Stock Watch: The Pandemic – Where Generics Failed To Reign
Big Generic Companies Seem To Have Suffered More Than Big Pharma
Executive Summary
If demand-side pressures on the life science sector were not enough, generic price erosion, debt repayment and extended restructurings are worsening the generic pharmaceutical investment proposition.
You may also be interested in...
Stock Watch: Amphastar’s Turn Away From Generics
Amphastar’s 2020 financial results included its best ever quarter and a different revenue pattern from most pharma and generic companies. Its evolving product mix and marketing campaigns were two reasons for its performance.
Stock Watch: The Pandemic’s Effects On Big Pharma – A Year In
Depending on the therapeutic area, a fall in pharmaceutical sales was an obvious effect of the pandemic, although lower selling and marketing expenses and fewer non-COVID-19 infections were minor positives.
Teva’s Complex Generic Ambitions Number Nearly A Dozen In 2021
Israeli giant Teva is hoping to follow the recent big-ticket launches of generic Truvada/Atripla and NuvaRing with multiple complex generics launches in the US this year. Management discussed individual product opportunities as Teva disclosed full-year financial earnings.